HC Wainwright Reaffirms “Buy” Rating for GeoVax Labs (NASDAQ:GOVX)

GeoVax Labs (NASDAQ:GOVX)‘s stock had its “buy” rating restated by equities research analysts at HC Wainwright in a report issued on Friday,Benzinga reports. They presently have a $8.00 price objective on the stock. HC Wainwright’s price objective indicates a potential upside of 206.51% from the stock’s previous close.

Several other research analysts also recently issued reports on the stock. EF Hutton Acquisition Co. I raised shares of GeoVax Labs to a “strong-buy” rating in a research report on Tuesday, July 23rd. Noble Financial upped their price target on shares of GeoVax Labs from $6.00 to $10.00 and gave the stock an “outperform” rating in a research note on Monday, August 19th. Finally, Alliance Global Partners assumed coverage on GeoVax Labs in a research report on Monday. They set a “buy” rating and a $15.00 target price on the stock. Four research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $13.25.

GeoVax Labs Trading Down 3.3 %

Shares of GOVX opened at $2.61 on Friday. The stock has a 50-day simple moving average of $2.39 and a 200-day simple moving average of $2.59. GeoVax Labs has a 1 year low of $1.09 and a 1 year high of $11.18.

GeoVax Labs (NASDAQ:GOVX) last posted its earnings results on Tuesday, November 12th. The company reported ($0.91) earnings per share for the quarter, topping the consensus estimate of ($1.29) by $0.38. The business had revenue of $2.79 million for the quarter, compared to analysts’ expectations of $1.84 million. During the same quarter in the previous year, the firm earned ($4.80) EPS. As a group, equities analysts predict that GeoVax Labs will post -5.1 earnings per share for the current year.

About GeoVax Labs

GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.